Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Seres Therapeutics, Inc. on June 18, 2020. The company is an emerging growth company incorporated in Delaware, with its common stock (MCRB) trading on The Nasdaq Global Select Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
A total of 66,492,568 shares were present at the meeting, representing approximately 92.1% of outstanding common stock as of the April 21, 2020 record date. The following proposals were approved:
- Item 1: Election of Class II Directors
- Stephen A. Berenson: Elected (59,514,136 votes FOR; 1,438,111 votes WITHHELD).
- Richard N. Kender: Elected (50,746,788 votes FOR; 10,205,459 votes WITHHELD).
- Meryl S. Zausner: Elected (50,071,707 votes FOR; 10,880,540 votes WITHHELD).
- Item 2: Ratification of Auditors
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2020.
- Votes: 66,388,045 FOR; 76,899 AGAINST; 27,624 ABSTAINED.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a standard disclosure of shareholder voting outcomes.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors (Stephen A. Berenson, Richard N. Kender, and Meryl S. Zausner) until the 2023 Annual Meeting.
- Confirm the appointment of PricewaterhouseCoopers LLP as the auditor for the fiscal year ending December 31, 2020.
- Note the significant number of broker non-votes (5,540,321) regarding the director elections, which did not affect the outcome but may indicate institutional voting patterns.